Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Iovance Biotherapeutics stock

Learn how to easily invest in Iovance Biotherapeutics stock.

Iovance Biotherapeutics Inc is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Iovance Biotherapeutics employs 319 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Iovance Biotherapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IOVA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Iovance Biotherapeutics stock price (NASDAQ: IOVA)

Use our graph to track the performance of IOVA stocks over time.

Iovance Biotherapeutics shares at a glance

Information last updated 2022-07-01.
Latest market close$11.47
52-week range$6.18 - $27.96
50-day moving average $12.10
200-day moving average $17.38
Wall St. target price$30.77
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.30

Buy Iovance Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Iovance Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Iovance Biotherapeutics price performance over time

Historical closes compared with the close of $11.47 from 2022-07-01

1 week (2022-06-28) 4.46%
1 month (2022-06-03) 46.11%
3 months (2022-04-01) N/A
6 months (2022-01-05) -31.81%
1 year (2021-07-02) -56.65%
2 years (2020-07-02) -60.57%
3 years (2019-07-05) 24.53
5 years (2017-07-05) 57.12%

Iovance Biotherapeutics financials

Gross profit TTM $0
Return on assets TTM -30.9%
Return on equity TTM -59.76%
Profit margin 0%
Book value $3.51
Market capitalisation $1.8 billion

TTM: trailing 12 months

Iovance Biotherapeutics share dividends

We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.

Have Iovance Biotherapeutics's shares ever split?

Iovance Biotherapeutics's shares were split on a 1:100 basis on 25 September 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.

Iovance Biotherapeutics share price volatility

Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $6.18 up to $27.96. A popular way to gauge a stock's volatility is its "beta".

IOVA.US volatility(beta: 0.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 0.9061. This would suggest that Iovance Biotherapeutics's shares are less volatile than average (for this exchange).

Iovance Biotherapeutics overview

Iovance Biotherapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M. D.

Frequently asked questions

What percentage of Iovance Biotherapeutics is owned by insiders or institutions?
Currently 0.47% of Iovance Biotherapeutics shares are held by insiders and 104.382% by institutions.
How many people work for Iovance Biotherapeutics?
Latest data suggests 319 work at Iovance Biotherapeutics.
When does the fiscal year end for Iovance Biotherapeutics?
Iovance Biotherapeutics's fiscal year ends in December.
Where is Iovance Biotherapeutics based?
Iovance Biotherapeutics's address is: 825 Industrial Road, San Carlos, CA, United States, 94070
What is Iovance Biotherapeutics's ISIN number?
Iovance Biotherapeutics's international securities identification number is: US4622601007
What is Iovance Biotherapeutics's CUSIP number?
Iovance Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 37182R102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site